<DOC>
	<DOCNO>NCT01603667</DOCNO>
	<brief_summary>The primary objective study evaluate efficacy PG2 Injection 500 mg versus placebo , administer intravenously within 3-6 hr stroke onset patient acute ischemic stroke , determine Modified Rankin Scale ( mRS ) score Day 90 . The secondary objective follow : - To evaluate efficacy PG2 Injection 500 mg versus placebo determine Barthel Index ( BI ) score Day 90 . - To evaluate efficacy PG2 Injection 500 mg reduce risk recurrent stroke , cardiovascular event death cause . - To evaluate safety PG2 Injection 500 mg treatment</brief_summary>
	<brief_title>PG2 Injection 500 mg Acute Stroke Study ( Pass )</brief_title>
	<detailed_description>Randomized , double-blind , placebo-controlled multi-center study intravenous ( IV ) PG2 Injection 500 mg start within 3-6 hr onset acute ischemic stroke</detailed_description>
	<mesh_term>Stroke</mesh_term>
	<criteria>1 . Patients present acute ischaemic stroke 2 . Patient , family member legally authorize responsibility , give inform consent 3 . Age ≥20 year 4 . Infusion study medication start within 36 hr stroke onset . 5 . NIHSS score ≥ 7 24 1 . Intracranial haemorrhage ( ICH ) identify CT MRI 2 . Rapidly improve symptom , particularly judgment manage clinician improvement likely result patient NIHSS score &lt; 6 randomization 3 . Prestroke mRS score ≥ 2 ( indicate previous disability ) 4 . Known allergy Astragalus membranaceus mayor derivative ( polysaccharide ) 5 . Patients eligible tPA treatment treat tPA . 6 . Participation investigational study previous 30 day 7 . Any terminal illness patient would expect survive 1 year 8 . Any condition could impose hazard patient study therapy initiate affect participation patient study ( applies patient severe microangiopathy haemolytic uremic syndrome thrombotic thrombocytopenic purpura ) . The judgment leave discretion Investigator 9 . Pregnant woman ( clinically evident ) 10 . Previous stroke within last three month 11 . Past history clinical presentation ICH , arteriovenous ( AV ) malformation , aneurysm , cerebral neoplasm . 12 . Current use oral anticoagulant prolong prothrombin time ( INR &gt; 1.6 ) 13 . Use heparin , except low dose subcutaneous heparin , previous 48 hr prolong activate partial thromboplastin time exceed upper limit local laboratory normal range 14 . Clinically significant hypoglycaemia ( blood sugar &lt; 50mg/dl ) 15 . Uncontrolled hypertension define blood pressure &gt; 185 mmHg systolic &gt; 110 mmHg diastolic least 2 separate occasion least 10 minute apart , require aggressive treatment reduce blood pressure within limit . The definition `` aggressive treatment '' leave discretion responsible Investigator 16 . Major surgery within precede 14 day pose risk opinion Investigator</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>